CONNECT WITH US
Web3 & Blockchain

Web3 & Blockchain

INJ Price Prediction: Rally improves, but derivatives stay cautious

Blockchain.News logo

Published on

Add as a preferred source on Google
INJ Price Prediction: Rally improves, but derivatives stay cautious

Injective is trading at $8.16, up 7.29% in the last 24 hours, and has moved back above its 7-, 20- and 50-day moving averages. Binance futures data is less supportive, with open interest down 10.62...

Market analysis includes conditional scenarios, not assured price outcomes or investment advice. Check the data, assumptions and dates cited.

Injective (INJ) is up 7.29% over the last 24 hours and is trading at $8.16, according to the supplied Binance spot data. That puts price above the 7-day SMA at $7.42, the 20-day SMA at $7.91 and the 50-day SMA at $7.74, which is a constructive short-term shift after recent weakness.

The move is not yet a clean breakout. INJ’s 24-hour range is $7.59 to $8.20, so the token is already trading near the top of its recent band, with immediate resistance at $8.38 and stronger resistance at $8.60.

The indicator mix is better, but not decisive. RSI at 56.17 points to a neutral-to-positive setup rather than an overextended one, while the MACD is essentially flat and the histogram is at zero. In plain terms, the bounce is real, but the trend is still in the process of confirming itself.

Stochastic is more extended, with %K at 89.16 and %D at 71.33. That suggests the latest push has been strong enough to lift momentum into the upper range of the short-term cycle, but it also leaves less room for immediate follow-through without a pause.

05. That placement supports a recovery narrative, but not one that looks stretched enough to ignore nearby resistance.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.